Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease in which the amount of emphysema and airway disease may be very different between individuals, even in end-stage disease. Emphysema formation may be linked to the involvement of the small pulmonary vessels. The NAPDH oxidase (Nox) family is emerging as a key disease-related factor in vascular diseases, but currently its role in hypoxia-induced pulmonary remodelling in COPD remains unclear. Here we investigate the role of p22phox, a regulatory subunit of Nox, in COPD lungs, hypoxic pulmonary vasoconstriction (HPV), hypoxia-induced pulmonary vascular remodelling and pulmonary hypertension. In COPD, compared to control lungs, p22phox expression was significantly reduced. The expression was correlated positively with mean pulmonary arterial pressure and oxygenation index and negatively with the diffusing capacity of the lung for carbon monoxide (p
Everything seems to make sense until you take into account hypoxic pulmonary vasoconstriction. For the sake of simplicity, imagine one entire lung has either dead space or pulmonary shunting and the other one is normal. In the case of dead space, the diseased lung will not have any perfusion. All that blood that is supposed to flow through that lung will flow through the normal lung. The normal lung will thus have 2x as much blood flowing through it. As a result, giving a patient in this... Why does 100% oxygen help patients with dead space but not pulmonary shunting?
Conclusion: Combined minimally invasive VATS fissure stapling with bronchoscopic valve placement to induce lobar atelectasis appears safe and feasible in the swine model. Future research in humans using a combined procedure is needed to confirm safety and clinical efficacy.
Conditions: Health Literacy; Hypertension Intervention: Behavioral: Health education tools combined with health literacy intervention Sponsor: Huzhou Normal University Not yet recruiting
Condition: Chronic Obstructive Pulmonary Disease Interventions: Other: Incremental shuttle walking protocol (ISWT); Other: Endurance shuttle walking (ESW) protocol; Other: First Intermittent shuttle walking protocol; Other: Second Intermittent shuttle walking protocol; Other: Focus group study Sponsors: Northumbria University; Royal Victoria Infirmary Not yet recruiting
Condition: Chronic Thromboembolic Pulmonary Hypertension Intervention: Procedure: Ballon pulmonary angioplasty Sponsor: Li Xuyan Recruiting
Conditions: Pulmonary Alveolar Proteinosis; COPD; Idiopathic Pulmonary Fibrosis; Viral Pneumonia; Coronavirus Infection; Interstitial Lung Disease Interventions: Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF); Device: Centricyte 1000; Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution; Drug: Liberase Enzyme (Roche); Drug: Sterile Normal Saline for Intravenous Use Sponsors: Healeon Me...
Conditions: Angina Pectoris; Acute Coronary Syndrome; Coronary Syndrome; Coronary Artery Disease; Angioplasty; Stent Restenosis; Hypertension; Heart Failure, Systolic; Depression, Anxiety; Covid-19; Isolation, Social Intervention: Other: Tele-medicine platform Sponsors: Professor Adrian Covic; Medical Sciences Academy - Romania; Victor Babes Clinical Hospital of Infectious Diseases - Bucharest Recruiting
Publication date: Available online 29 March 2020Source: Pregnancy HypertensionAuthor(s): Sonja Suvakov, Emma Bonner, Valentina Nikolic, Djurdja Jerotic, Tatjana P Simic, Vesna D Garovic, Guillermo Lopez-Campos, Lana McClements
(CNN) — It’s a scenario all too many of us are facing — or will soon face. You or a loved one has a mild fever, body aches, the start of a nagging, dry cough. Food doesn’t taste good nor smell as it once did. Maybe you have shortness of breath or struggle to breath deeply. You’ve called your doctor, and you are suddenly face-to-face with the scary reality of Covid-19. What happens next depends on your specific circumstances. If you are having trouble breathing or are elderly and fragile, you may be hospitalized and tested for the virus. If you’re not in immediate danger but potentially h...
NEW BRUNSWICK, N.J., March 30, 2020 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson &Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its le...